Legend Biotech Corp. (LEGN)
20.95
-0.87
(-3.99%)
USD |
NASDAQ |
Aug 24, 16:00
21.31
+0.36
(+1.72%)
After-Hours: 20:00
Legend Biotech Enterprise Value : 3.542B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 3.542B |
| August 20, 2026 | 3.433B |
| August 19, 2026 | 3.693B |
| August 18, 2026 | 3.561B |
| August 17, 2026 | 3.315B |
| August 14, 2026 | 3.261B |
| August 13, 2026 | 3.241B |
| August 12, 2026 | 3.315B |
| August 11, 2026 | 3.544B |
| August 10, 2026 | 3.317B |
| August 07, 2026 | 3.334B |
| August 06, 2026 | 3.049B |
| August 05, 2026 | 3.005B |
| August 04, 2026 | 3.020B |
| August 03, 2026 | 2.997B |
| July 31, 2026 | 2.908B |
| July 30, 2026 | 3.005B |
| July 29, 2026 | 2.966B |
| July 28, 2026 | 3.003B |
| July 27, 2026 | 3.048B |
| July 24, 2026 | 3.619B |
| July 23, 2026 | 3.873B |
| July 22, 2026 | 3.873B |
| July 21, 2026 | 3.875B |
| July 20, 2026 | 3.811B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.627B |
| July 16, 2026 | 3.714B |
| July 15, 2026 | 3.778B |
| July 14, 2026 | 4.288B |
| July 13, 2026 | 4.303B |
| July 10, 2026 | 4.561B |
| July 09, 2026 | 4.619B |
| July 08, 2026 | 4.714B |
| July 07, 2026 | 4.677B |
| July 06, 2026 | 4.747B |
| July 02, 2026 | 5.109B |
| July 01, 2026 | 5.105B |
| June 30, 2026 | 4.910B |
| June 29, 2026 | 5.014B |
| June 26, 2026 | 4.884B |
| June 25, 2026 | 4.835B |
| June 24, 2026 | 5.012B |
| June 23, 2026 | 4.997B |
| June 22, 2026 | 5.004B |
| June 18, 2026 | 4.742B |
| June 17, 2026 | 5.781B |
| June 16, 2026 | 5.755B |
| June 15, 2026 | 6.145B |
| June 12, 2026 | 6.217B |
| June 11, 2026 | 6.293B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 532.50B |
| Dianthus Therapeutics, Inc. | 5.203B |
| Gilead Sciences, Inc. | 202.61B |
| Ironwood Pharmaceuticals, Inc. | 1.027B |
| Arbutus Biopharma Corp. | 940.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 33.25M |
| Revenue (Quarterly) | 388.14M |
| Total Expenses (Quarterly) | 354.89M |
| EPS Diluted (Quarterly) | 0.1716 |
| Gross Profit Margin (Quarterly) | 61.52% |
| Profit Margin (Quarterly) | 8.57% |
| Earnings Yield | -2.41% |
| Normalized Earnings Yield | -2.354 |